Editorial Comment: Overall survival prediction in metastatic castration resistant prostate cancer treated with radium-223.
作者信息
Dos Reis Rodolfo Borges, Muglia Valdair, Faria Eliney F
机构信息
Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirão Preto - USP, Ribeirão Preto, SP, Brasil.
Departamento de Imagens Médicas, Radioterapia e Onco-hematologia. Faculdade de Medicina de Ribeirão Preto - USP, Ribeirão Preto, SP, Brasil.
出版信息
Int Braz J Urol. 2020 Jul-Aug;46(4):612-613. doi: 10.1590/S1677-5538.0343.1.
Abstract
摘要
相似文献
1
Editorial Comment: Overall survival prediction in metastatic castration resistant prostate cancer treated with radium-223.编者按：镭-223治疗转移性去势抵抗性前列腺癌的总生存预测
Int Braz J Urol. 2020 Jul-Aug;46(4):612-613. doi: 10.1590/S1677-5538.0343.1.
2
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.镭-223 联合治疗转移性去势抵抗性前列腺癌患者：一项国际性、早期准入、开放标签、单臂 3b 期试验。
Lancet Oncol. 2016 Sep;17(9):1306-16. doi: 10.1016/S1470-2045(16)30173-5. Epub 2016 Jul 26.
3
Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice.镭-223用于转移性去势抵抗性前列腺癌：临床开发及在当代实践中的应用
J Med Imaging Radiat Sci. 2019 Dec;50(4S1):S26-S30. doi: 10.1016/j.jmir.2019.05.006. Epub 2019 Jun 21.
4
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.反驳观点：在有症状的转移性去势抵抗性前列腺癌中，多西他赛和镭-223应首先使用哪一种？镭-223是骨转移为主的有症状转移性去势抵抗性前列腺癌的首选治疗方法。
Clin Adv Hematol Oncol. 2015 May;13(5):293-8.
5
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.镭-223 联合醋酸阿比特龙和泼尼松或泼尼松龙治疗去势抵抗性前列腺癌和骨转移患者（ERA 223）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet Oncol. 2019 Mar;20(3):408-419. doi: 10.1016/S1470-2045(18)30860-X. Epub 2019 Feb 6.
6
Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.循环肿瘤细胞作为生存和镭-223 治疗反应的生物标志物：转移性去势抵抗性前列腺癌患者队列的经验。
Clin Genitourin Cancer. 2018 Dec;16(6):e1133-e1139. doi: 10.1016/j.clgc.2018.07.013. Epub 2018 Jul 21.
7
Response to comment on "Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer".
Eur J Cancer. 2021 Feb;144:395-396. doi: 10.1016/j.ejca.2020.11.041. Epub 2020 Dec 25.
8
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.对立观点：在有症状的转移性去势抵抗性前列腺癌中，多西他赛和镭-223哪个应首先使用？多西他赛仍是有症状的转移性去势抵抗性前列腺癌的最佳首选。
Clin Adv Hematol Oncol. 2015 May;13(5):293-5.
9
Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.镭-223 在转移性去势抵抗性前列腺癌中的最佳应用。
J Formos Med Assoc. 2017 Nov;116(11):825-836. doi: 10.1016/j.jfma.2017.04.005. Epub 2017 Oct 16.
10
Radium 223 for the treatment of metastatic castration-resistant prostate cancer.镭223用于治疗转移性去势抵抗性前列腺癌。
Arch Esp Urol. 2019 Jun;72(5):500-507.
本文引用的文献
1
Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223.镭-223 治疗转移性去势抵抗性前列腺癌的总生存预测。
Int Braz J Urol. 2020 Jul-Aug;46(4):599-611. doi: 10.1590/S1677-5538.IBJU.2019.0343. Epub 2020 Mar 15.
2
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.晚期前列腺癌患者的管理：2019年晚期前列腺癌共识会议报告
Eur Urol. 2020 Apr;77(4):508-547. doi: 10.1016/j.eururo.2020.01.012. Epub 2020 Jan 27.
3
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.镭-223 联合醋酸阿比特龙和泼尼松或泼尼松龙治疗去势抵抗性前列腺癌和骨转移患者（ERA 223）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet Oncol. 2019 Mar;20(3):408-419. doi: 10.1016/S1470-2045(18)30860-X. Epub 2019 Feb 6.
4
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.镭-223 治疗去势抵抗性前列腺癌伴骨转移无症状患者的国际早期准入项目。
BMC Cancer. 2019 Jan 7;19(1):12. doi: 10.1186/s12885-018-5203-y.
5
[Biomarkers in metastatic castration-resistant prostate cancer].[转移性去势抵抗性前列腺癌中的生物标志物]
Aktuelle Urol. 2015 Jan;46(1):66-70. doi: 10.1055/s-0034-1396859. Epub 2015 Feb 6.
6
Alpha emitter radium-223 and survival in metastatic prostate cancer.α 粒子发射体镭-223 与转移性前列腺癌的生存。
N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755.
7
Mechanisms of bone metastasis.骨转移的机制。
Discov Med. 2004 Jun;4(22):144-8.
Zotero 插件